Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVDA Trial for Plasmodium Falciparum Malaria Transmission
NCT06068530Phase 4Recruiting
- Sponsor
- University of Oxford
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of R21/Matrix-M, dihydroartemisinin + piperaquine, primaquine in malaria, sponsored by University of Oxford. Started Feb 2025; status: recruiting.
02
Drugs
R21/Matrix-Mdihydroartemisinin + piperaquineprimaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06068530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068530.